Clinical trial · Observational
Immunity to Infection in Healthy Participants and Participants With Cancer
Systems Biology Analysis of Vaccine-induced Immunity to Infectious Diseases in Healthy Participants and Participants With Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Many cancer patients are highly susceptible to infection and respond poorly to vaccination. This observational study will determine molecular and cellular features of immunity to viral pathogens in participants with cancer and compare them to healthy controls. The aim is to identify how antiviral immunity in participants with cancer differs from that in healthy participants to understand why cancer patients are more susceptible to infections. In this context, the investigators will also evaluate immunity to medically indicated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal influenza vaccine received by study participants during standard care (vaccines are not part of the study).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Influenza | — | UNRESOLVED | — |
| SARS-CoV-2 | — | UNRESOLVED | — |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological sample collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Healthy participants
- description
- Healthy adults aged \> 18 years
- interventionNames
- Procedure: Biological sample collection
- label
- Participants with haematological malignancies
- description
- Multiple myeloma patients receiving lenalidomide and smoldering multiple myeloma patients under observation.
- interventionNames
- Procedure: Biological sample collection
- label
- Participants with solid tumours
- description
- Stage IV non-small cell lung cancer patients treated with checkpoint inhibitor therapy +/- chemotherapy.
- interventionNames
- Procedure: Biological sample collection
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * You are aged 18 years or older. * You are able to understand and give informed consent. * Participants with cancer: you are suffering from cancer * Healthy participants: you are a healthy individual. Exclusion Criteria: * You are unable to give informed consent. * You have been suffering from an acute infection with fever during the last three days. * You have a Hb level of less than 9 g/dl. * You have a human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection.
References
Publications (0)
Data not yet available